The proposed invention is based upon a theory in medicine, first proposed in 1908 by Paul Ehrlich that all cancers are a form of immune system malfunction. This was not seriously looked at until late 1950s when additional evidence to support this hypothesis was published. By the early 80’s, advances in biotechnology led to further understanding, and today it is believed that the immune system protects us from cancers via Immune Surveillance and Immune Editing. Immune Surveillance leads to Immune Editing, i.e. the immune system’s strategies to overcome the cancer. In all of us who don’t succumb to cancer, Immune Editing is successful in its elimination phase. When Immune Editing’s elimination phase fails, it leads to Immune Escape (cancer escaping from the clutches of the immune system altogether.) Following is a synopsis of the various stages. ImmunoScience’s scientists believe that by using techniques to enhance cancer Immune Editing, Immune Escape can be prevented or eliminated in order to get an upper hand on most cancers.
At the present time, several researchers are working on various approaches to immunological approaches to various cancers. These consist of monoclonal antibodies targeting one type of cancer and these have been successful only in attaining remissions but have generally not been successful in functional cures with a permanent remission. Another approach that has not been successful has been giving vectors expressing a mucin found in epithelial cancers. This approach has failed because of mutations in the mucin and inability of the immune system to attack the cancers because of some defenses of the cancer cells. A third approach involves taking a patient’s cancer cells and the same patient’s immune cells and cocultivating them in a lab with some immune enhancing methodologies and then injecting them back into the patient. This approach has had some success but not a lasting one thus requiring this treatment to be given in perpetuity, at least in theory.
ImmunoScience plans to create a long term infection with a vector that expresses markers of various cancers (either as a polyvalent vaccine or as a monovalent vaccine depending upon research) and, at the same time, disable many of the mechanisms used by cancer cells to evade the immune system. This makes ImmunoScience’s cancer immunotherapy unique and with a very high probability of success. It is anticipated that fewer repeat doses will be needed and functional cure attainable even in late stages of cancer, despite widely spread metastases. This will be achieved without the side effects of current chemotherapy because our vaccine has no toxic pharmacological effects on a human body.